Uric acid levels predict death in acute coronary syndrome

Uric acid levels predict death in acute coronary syndrome
Elevated uric acid levels are predictive of one-year mortality in patients with acute coronary syndrome, according to a study published in the May 1 issue of The American Journal of Cardiology.

(HealthDay) -- Elevated uric acid levels are predictive of one-year mortality in patients with acute coronary syndrome, according to a study published in the May 1 issue of The American Journal of Cardiology.

Gjin Ndrepepa, M.D., of the Deutsches Herzzentrum in Munich, Germany, and colleagues conducted a study involving 5,124 patients with who underwent percutaneous coronary intervention (PCI) to evaluate whether uric acid levels have any prognostic value in this patient population. Of the participants, 1,629 had acute ST-segment elevation (STEMI), 1,332 had acute non-STEMI, and 2,163 had . Participants were classified into four uric acid quartiles: quartile 1 (1.3 to <5.3 mg/dL), quartile 2 (5.3 to <6.3 mg/dL), quartile 3 (6.3 to <7.5 mg/dL), and quartile 4 (7.5 to 18.4 mg/dL). One-year mortality was the primary end point.

During follow-up, the researchers identified 450 deaths: 80 deaths in quartile 1, 77 in quartile 2, 72 in quartile 3, and 221 in quartile 4 (unadjusted hazard ratio, 3.05 for fourth versus first quartile uric acid). The association between uric acid and mortality persisted after adjustment, with every 1-mg/dL increase in the uric acid level correlating with a 12 percent increase in the adjusted risk for one-year mortality.

"Elevated levels of uric acid are an independent predictor of one-year mortality across the whole spectrum of patients with acute coronary syndromes treated with percutaneous coronary intervention," the authors write.

More information: The American journal of cardiology, 1 May 2012, v. 109, 9 , pp. 1260-1265. DOI: 10.1016/j.amjcard.2011.12.018)

Related Stories

Some heart attack rates declining and survival improving

date Jan 12, 2011

Coronary syndromes vary in severity, ranging from unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), to ST-segment elevation myocardial infarction (STEMI), the most severe diagnosis. Little data exist ...

Recommended for you

1950s drug is future heart treatment

date 23 hours ago

Oxford University researchers have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Time is muscle in acute heart failure

date May 21, 2015

Urgent diagnosis and treatment in acute heart failure has been emphasised for the first time in joint recommendations published today in European Heart Journal.

Common mutation linked to heart disease

date May 20, 2015

A common mutation in a gene that regulates cholesterol levels may raise the risk of heart disease in carriers, according to a new UConn Health study.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.